Document:

<PAGE>

                                                                 Exhibit 10.14

     Confidential Materials omitted and filed separately with the Securities
              and Exchange Commission. Asterisks denote omissions.

                                 AMENDMENT NO. 4

                                       to

                                    AGREEMENT

                                 by and between

                  BAYER AG AND MILLENNIUM PHARMACEUTICALS, INC.

         This is Amendment No. 4, dated as of December 1, 2000 ("Amendment No.
4"), to the Agreement, dated as of September 22, 1998 and as subsequently
amended (the "Agreement"), by and between Bayer AG, located at D 51368
Leverkusen, Germany and Millennium Pharmaceuticals, Inc., located at 75 Sidney
Street, Cambridge, Massachusetts 02139.

                                  INTRODUCTION

         The Parties have determined that it is in their mutual best interests
to amend the Agreement in the manner set forth below.

         Accordingly, in accordance with Section 11.5 of the Agreement, the
Parties agree to amend the Agreement as follows:

         1. Use of Terms. Capitalized terms used herein and not defined herein
shall have the respective meanings ascribed to such terms in the Agreement.

         2. Exhibit D. Exhibit D of the Agreement is hereby amended by
deleting Exhibit D in its entirety and by substituting the following in its
place:

                            Program Payment Schedule

                     Date                                Payment Due
                     ----                                -----------
                     February 1, 1999                    $[**]
                     May 1, 1999                         $[**]
                     August 1, 1999                      $[**]

                     November 1, 1999                    $[**]
                     December 1, 1999                    $[**]
                     February 1, 2000                    $[**]
                     May 1, 2000                         $[**]
                     August 1, 2000                      $[**]

<PAGE>

     Confidential Materials omitted and filed separately with the Securities
              and Exchange Commission. Asterisks denote omissions.

                    November 1, 2000                     $[**]
                    December 8, 2000                     $[**]
                    February 1, 2001                     $[**]
                    May 1, 2001                          $[**]
                    August 1, 2001                       $[**]

                    November 1, 2001                     $[**]
                    February 1, 2002                     $[**]
                    May 1, 2002                          $[**]
                    August 1, 2002                       $[**]

                    November 1, 2002                     $[**]
                    February 1, 2003                     $[**]
                    May 1, 2003                          $[**]
                    August 1, 2003                       $[**]

         2. General. In all other respects, the Agreement is hereby ratified and
confirmed.

         IN WITNESS WHEREOF, the Parties have executed this Amendment No. 4 as
of the date set forth above.

                                    BAYER AG

                                    By: /s/ WOLFGANG HARTWIG
                                        -----------------------------
                                    Title: Prof. Dr. Wolfgang Hartwig

                                    By: /s/ HELMUT PASTOR
                                        -----------------------------
                                    Title:  Senior Counsel

                                    MILLENNIUM PHARMACEUTICALS, INC.

                                    By: /s/ KEVIN STARR
                                        -----------------------------
                                    Title:  Chief Financial Officer

                                                        -2-<PAGE>

                                                                 Exhibit 10.18

     Confidential Materials omitted and filed separately with the Securities
              and Exchange Commission. Asterisks denote omissions.

                      FIRST AMENDMENT OF COLLABORATION AND
                                LICENSE AGREEMENT

         This First Amendment of Collaboration and License Agreement (the "First
Amendment"), effective as of November 17, 2000, is made by and between Becton,
Dickinson and Company, a corporation organized and existing under the laws of
New Jersey and having its principal office at 1 Becton Drive, Franklin Lakes,
New Jersey 07417 ("BD"), and Millennium Predictive Medicine, Inc., a corporation
organized and existing under the laws of Delaware and having its principal
office at One Kendall Square, Cambridge, Massachusetts 02139 ("MPMx").

         BD and MPMx are parties to a certain Collaboration and License
Agreement dated February 21, 1999 (the "Agreement").

         BD and MPMx desire to amend a provision of the Agreement.

         NOW, THEREFORE, BD and MPMx agree as follows:

         1. The Additional Payment of [**] Dollars ($[**]) payable by BD to MPMx
on the second anniversary of the Effective Date, pursuant to Section 4.2 of the
Agreement, shall be deferred and become due and payable by BD to MPMx on October
1, 2001 in lieu of on February 21, 2001.

         2. All other terms and conditions of the Agreement shall remain in full
force and effect. Further, the consent pertaining to the Agreement dated October
20, 2000 shall remain in full force and effect.

         In WITNESS WHEREOF, BD and MPMx have executed this First Amendment as
of the date first set forth above.

BECTON, DICKINSON AND COMPANY

By:      /s/ VINCENT A. FORLENZA
         ---------------------------------
         Vincent A. Forlenza
         Senior Vice President Technology,
         Strategy and Development

MILLENNIUM PREDICTIVE MEDICINE, INC.

By:      /s/ KENNETH J. CONWAY
         ---------------------------------
         Kenneth J. Conway, President<PAGE>

                                                                 Exhibit 10.19

     Confidential Materials omitted and filed separately with the Securities
              and Exchange Commission. Asterisks denote omissions.

                      SECOND AMENDMENT OF COLLABORATION AND
                                LICENSE AGREEMENT

         This Second Amendment of Collaboration and License Agreement (the
"Second Amendment"), effective as of December 20, 2000, is made by and between
Becton, Dickinson and Company, a corporation organized and existing under the
laws of New Jersey and having its principal office at 1 Becton Drive, Franklin
Lakes, New Jersey 07417 ("Becton Dickinson"), and Millennium Predictive
Medicine, Inc., a corporation organized and existing under the laws of Delaware
and having its principal office at One Kendall Square, Cambridge, Massachusetts
02139 ("MPMx").

         WHEREAS, Becton Dickinson and MPMx are parties to a certain
Collaboration and License Agreement dated February 21, 1999 (the "Agreement");

         WHEREAS, in accordance with Section 2.8(a) of the Agreement, the Joint
Steering Committee (as defined in the Agreement) has agreed upon an adjustment
to the Year [**] Milestone (as defined in the Agreement); and

         WHEREAS, Becton Dickinson and MPMx desire to confirm the adjustment
to the Year [**] Milestone;

         NOW, THEREFORE, Becton Dickinson and MPMx agree as follows:

         1. Exhibit C to the Agreement is hereby deleted in its entirety and the
attached Exhibit C is hereby substituted in lieu thereof.

         2. All other terms and conditions of the Agreement shall remain in full
force and effect. Further, the consent pertaining to the Agreement dated October
20, 2000 shall remain in full force and effect.

         In WITNESS WHEREOF, Becton Dickinson and MPMx have executed this Second
Amendment as of the date first set forth above.

BECTON, DICKINSON AND COMPANY

By:      /s/ VINCENT A. FORLENZA
         -----------------------------
         Vincent A. Forlenza, Senior Vice President Technology,
         Strategy and Development

MILLENNIUM PREDICTIVE MEDICINE, INC.

By:      /s/ KENNETH J. CONWAY
         -----------------------------
         Kenneth J. Conway, President

<PAGE>

     Confidential Materials omitted and filed separately with the Securities
              and Exchange Commission. Asterisks denote omissions.

                                    EXHIBIT C

                               YEAR [**]MILESTONE

 a.      Year [**] Milestone Composition.

         i. The Year [**] Milestone consists of [**], all more fully described
 below. Successful achievement of the Year [**] Milestone by MPMx shall occur
 once it has been determined that all the requirements for each component
 ("Requirements") have been met by [**].

        ii. Specific Components of the Year [**] Milestone.

            (a) [**]

                (i) The Requirements for fulfilling the [**] component
(collectively, the "[**] Requirement") shall consist of subsections(a)(ii),
(a)(iii), (a)(iv) and (a)(v) below.

               (ii) At least [**] of the research projects ("Research Projects")
identified below shall meet the requirements applicable to such Research
Projects:

               (A) [**] MPMx will [**] and will have [**].

               (B) [**] MPMx will [**] and will have [**].

               (C) [**] MPMx will [**] and will have [**].

               (D) [**] MPMx will [**] will be [**].

               (E) [**] MPMx will [**] will be [**].

               (F) [**] MPMx shall [**] will be [**].

             (iii) The Research Projects meeting the requirements applicable
to such Research Projects identified in subsection (a)(ii) shall include [**].

              (iv) For all of the Research Projects (on a combined basis), the
research [**] described in the Research Plans for such Research Projects shall
[**] agreed to by the Joint Steering Committee for such Research Projects.

                                       -2-

<PAGE>

     Confidential Materials omitted and filed separately with the Securities
              and Exchange Commission. Asterisks denote omissions.

                (v) For all of the Research Projects (on a combined basis),
[**] set forth in the Research Plans shall [**] agreed to by the Joint
Steering Committee for the Research Plans for such Research Projects.

            (b) [**]

                (i) The Requirements for fulfilling the [**]component
(collectively, the [**] Requirement") shall consist of subsections (b)(ii) and
(b)(iii) below.

               (ii) [**] under the Research Program have been [**].

              (iii) [**] under the Research Program have, [**].

            (c) [**]

                (i) The Requirements for fulfilling the [**] component ([**]
Requirement") shall consist of subsections (c)(ii) and (c) (iii) below.

               (ii) Becton Dickinson will provide MPMx with [**]. No later
than [**], the Parties shall by mutual agreement (a) [**] of the [**] for the
Product Areas listed below; or (b) agree to [**]; or (c) agree to [**].
Specifically, [**] for purposes of subsection (c)(iii) below shall [**].

              (iii) In the event that the [**], and provided further that [**]
that are estimated to provide [**]

               (iv) For purposes of subsections (c)(ii) and (c)(iii) only (and
for no other purpose of the Agreement), [**] under the Agreement [**]

                 b. Adjustments to the Year [**] Milestone Notwithstanding
anything to the contrary in this Exhibit C, as a condition precedent to MPMx's
timely performance of its obligations with respect to the [**] as described in
each Research Plan [**] for such Requirements [**].

                                                        -3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00021-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00021-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00021-of-00352.parquet"}]]